Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 17/20 | 0.85 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.85 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5879331 | 0.94 | OPRD1 (0.75) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL6110626 | 0.92 | OPRD1 (0.81) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL4996395 | 0.91 | OPRD1 (0.82) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL6110756 | 0.90 | OPRD1 (0.75) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL6111307 | 0.89 | OPRD1 (0.76) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL5727389 | 0.87 | OPRD1 (0.66) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL4932328 | 0.87 | OPRD1 (0.73) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL6111087 | 0.87 | OPRD1 (0.71) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL6109933 | 0.86 | OPRD1 (0.72) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL6109372 | 0.86 | OPRD1 (0.72) | OPRD1OPRM1KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154964-A1 | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | US | claimed |
| EP-1587790-A2 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2005-10-26 | — | — | EP | claimed |
| WO-2004062562-A2 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | WO | claimed |
| US-20060154964-A1 | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154964-A1 | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | OPRM1, OPRD1, OPRL1 | OPRD1 2/4885OPRM1 1/4885KCNH2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.